Peer-reviewed veterinary case report
Yixiao Formula Suppresses Myocardial Fibrosis Through UpregulatingmiR-133a and Downregulating TGF-/Smads Signal Molecules.
- Journal:
- Journal of diabetes research
- Year:
- 2026
- Authors:
- Zhao, Qiyao et al.
- Affiliation:
- Department of Nephrology and Endocrine (II) · China
- Species:
- rodent
Abstract
BACKGROUND: Yixiao formula (YXF), a traditional Chinese herbal medicine, has demonstrated clinical efficacy in alleviating symptoms of diabetic cardiomyopathy (DCM). The therapeutic mechanism underlying YXF's effects on DCM remains poorly understood. Myocardial fibrosis is a key pathogenic mechanism in DCM, and previous studies have indicated that miR-133a may be involved in its progression. Given that the TGF-/Smads signaling pathway is a well-established mediator of myocardial fibrosis, investigating the mechanistic role of YXF through miR-133a and the TGF-/Smads pathway warrants further exploration. OBJECTIVE: The main objective of this study is to investigate the potential contribution of the TGF-/Smads pathway to the effects of YXF, as well as the role of miR133a, through in vivo DCM models and in vitro experiments. MATERIALS AND METHODS: Spontaneously diabetic KKAy mice were used to establish a DCM model by continuous high-fat feeding, with C57BL/6 mice as controls. Echocardiography, body weight, and blood glucose data were collected every 4 weeks to examine the effects of YXF on blood glucose levels and changes in cardiac function and structure in DCM mice. Immunohistochemistry, RT-qPCR, and western blot were used to detect the expression levels of the TGF-/Smads pathway. Additionally, the potential molecular mechanism of YXF in mouse cardiac fibroblasts (MCFs) was investigated by knocking down miR-133a. RESULTS: YXF improved fasting blood glucose levels in DCM mice, promoted cardiac diastolic function, upregulated miR133a, and inhibited the expression of the TGF-/Smads pathway. Furthermore, when miR133a inhibitors were transfected under YXF intervention, we found that YXF's inhibitory effect on the TGF-/Smads pathway was weakened. CONCLUSION: Through this study, we found that YXF can increase miR133a and inhibit the expression of the TGF-/Smads pathway, thereby inhibiting myocardial fibrosis and exerting a protective effect on DCM.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/41573701/